Form 4: Ligand Pharmaceuticals Director John L. LaMattina Reports Acquisition of Stock Options and Restricted Stock Units

Director John L. LaMattina reports acquisition of stock options and restricted stock units in Ligand Pharmaceuticals.

Summary

• On June 14, 2024, John L. LaMattina, a director of Ligand Pharmaceuticals Inc., reported the acquisition of 1,252 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted by the Board of Directors at their annual meeting and will fully vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date.
• LaMattina also acquired 5,444 non-qualified stock options with an exercise price of $80.06, also granted on June 14, 2024.
• These options also vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date and expire on June 14, 2034.
• Following these transactions, LaMattina directly owns 29,515 shares of common stock and 5,444 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction of stock options and RSUs, which is a normal part of executive compensation. It doesn't indicate any significant positive or negative implications for the company.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Future Outlook

The RSUs and stock options vest on the earlier of the next annual meeting of the Company stockholders following the grant date or on the first anniversary of the date of grant.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedules for these grants, typically tied to annual meetings or one-year anniversaries, are also standard practice.

Stakeholder Impact

• The acquisition of stock options and RSUs aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates